Promega announced today that it is collaborating with GSK, a global biopharma company, to plan, develop and commercialize a microsatellite instability (MSI) companion diagnostic (CDx) IVD kit.

According to a release the kit will identify adult cancer patients with MSI-H solid tumors who may be eligible for potential treatment with GSK’s Jermperli, an anti-PD-1 monoclonal antibody.

“This collaboration underscores our commitment to enabling patient access to targeted therapies,” Promega Global Clinical Market Director Alok Sharma said in a statement. “The results of our MSI biomarker test will be a critical step to identifying patients who may be eligible to receive this drug marketing by GSK.

The kit distribution timeline was not disclosed.